Join
Live feed
·
PRReleasevia Quantisnow
Sagimet Biosciences Inc. logo

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

ByQuantisnow·Wall Street's wire, on your screen.
SGMT· Sagimet Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGMT (Sagimet Biosciences Inc.) and more on Quantisnow.